BPS Publiions
· Notably, the suppression of blood eosinophil counts was more prolonged in the 100 and 300 mg dose groups, with adjusted reductions in blood eosinophil count compared with placebo of 82% and 83%, respectively, at week 26; these reductions are similar to the approximately 84% reduction observed with mepolizumab versus placebo at week 32 following 4weekly repeat dosing during the Phase 3 .